articleThe Lancet NeurologyFeb 27, 2010Closed access

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Turku University Hospital · Turku PET Centre · +9 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

No related works found for this paper.